Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting

Melanoma and Skin CancerPsoriasis

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries

J Eur Acad Dermatol Venereol.

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC

doi: 10.1111/jdv.15203.

Acne

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

J Eur Acad Dermatol Venereol

Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C

doi: 10.1111/jdv.17598

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

J Eur Acad Dermatol Venereol.

Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barri S, Muñoz C, Llamas M, Valentí F, Josune Mitxelena M, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Manuel Carrascosa J

doi: 10.1111/jdv.16439.

Further Publications Dermatology

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

J Am Acad Dermatol

Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ

doi: 10.1016/j.jaad.2021.06.878

Spinal Disorders

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

Rheumatology (Oxford).

Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estévez E, Katsifis G, VanLunen B, Kleine E, Hoepken B, Bauer L, Goodson N

doi: 10.1093/rheumatology/keaa181.

Psoriasis

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Lancet.

Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D

doi: 10.1016/

Rheumatoid Arthritis

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Ann Rheum Dis.

Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH

doi: 10.1136/annrheumdis-2019-215764.

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Related content

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)